Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
1. Wegovy® shows 57% heart attack risk reduction versus tirzepatide. 2. Real-world STEER study confirms cardiovascular benefits of semaglutide. 3. 29% overall risk reduction reported for Wegovy® compared to tirzepatide. 4. Novo Nordisk highlights Wegovy's unique heart-protective efficacy. 5. Obesity-related cardiovascular deaths are on the rise globally.